MarketScreener Homepage > Equities > Xetra > Evotec SE EVT DE0005664809

Report

Real-time Estimate Tradegate - 10/23 04:39:24 am
22.925	EUR		-1.10%

10/20

EVOTEC SE : Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

10/19

EVOTEC : Topas Therapeutics Raises € 22 m (~US$ 26 m) in Series B Financing and appoints Klaus Martin, Ph.D. as Chief Executive Officer

10/19

EVOTEC : Topas Therapeutics Raises € 22 m (~US$ 26 m) in Series B Financing

Summary

Quotes 5-day view Delayed Quote.

Delayed Xetra

10/19/2020	10/20/2020	10/21/2020	10/22/2020	10/23/2020	Date
23.37(c)	23.13(c)	23.04(c)	23.18(c)	22.98	Last
618 286	609 331	894 590	1 293 172	425 461	Volume
+1.39%	-1.03%	-0.39%	+0.61%	-0.86%	Change

More quotes

Financials

Sales 2020	478 M 564 M 564 M
Net income 2020	30,0 M 35,3 M 35,3 M
Net Debt 2020	145 M 171 M 171 M
P/E ratio 2020	118x
Yield 2020	-

Sales 2021	547 M 645 M 645 M
Net income 2021	48,5 M 57,2 M 57,2 M
Net Debt 2021	88,3 M 104 M 104 M
P/E ratio 2021	72,6x
Yield 2021	-

Capitalization	3 781 M 4 473 M 4 460 M
EV / Sales 2020	8,21x
EV / Sales 2021	7,07x
Nbr of Employees	3 278
Free-Float	90,7%

More Financials

Company

Evotec SE specializes in research and development services for the pharmaceutical and biotechnological industries. The group's activity is organized around 3 areas: - development of broadband screening systems; - research and development of pharmaceutical products: for the neurologic, oncologic, inflammatory diseases treatment; - other: target identification, pharmacological tests development, broadband screening...

Sector

Biotechnology & Medical Research

Calendar

11/12

Earnings Release

More about the company

Notations Surperformance© of Evotec SE

Trading Rating :

Investor Rating :

More Ratings

All news about EVOTEC SE

10/20	EVOTEC SE : Release according to Article 41 of the WpHG [the German Securities T..	EQ
10/19	EVOTEC : Topas Therapeutics Raises € 22 m (~US$ 26 m) in Series B Financing and ..	PU
10/19	EVOTEC : Topas Therapeutics Raises € 22 m (~US$ 26 m) in Series B Financing	PU
10/19	EVOTEC : Topas Therapeutics Raises €22 Million (~USD 26 Million) in Series B Fin..	PU
10/19	EVOTEC : Baader Bank keeps its Buy rating	MD
10/19	EVOTEC : secures grant to evaluate antibody drugs for COVID-19	RE
10/19	EVOTEC : Just - evotec biologics receives grant to enable an antibody product fo..	EQ
10/13	EVOTEC : Buy rating from RBC	MD
10/13	EVOTEC : Baader Bank gives a Buy rating	MD
10/12	EVOTEC : Mubadala investment company and novo holdings a/s invest € 250 m in evo..	PU
10/12	EVOTEC : Mubadala Investment Company and Novo Holdings A/S invest € 250 million ..	PU
10/12	EVOTEC : Mubadala investment company and novo holdings a/s invest ? 250 m in evo..	EQ
10/12	EVOTEC : Mubadala Investment Company and Novo Holdings A/S invest ? 250 million ..	EQ
10/12	EVOTEC SE : Release according to Article 40, Section 1 of the WpHG [the German S..	EQ
10/09	EVOTEC SE : Release according to Article 40, Section 1 of the WpHG [the German S..	EQ

More news

News in other languages on EVOTEC SE

10/21	BAYER IM FOKUS : Warten auf das Licht am Ende des Tunnels
10/19	Aktien Frankfurt Schluss: Dax im Minus
10/19	DPA-AFX-ÜBERBLICK : UNTERNEHMEN vom 19.10.2020 - 15.15 Uhr
10/19	Aktien Frankfurt: Dax gerät im Verlauf unter Druck
10/19	EVOTEC : Topas Therapeutics erhält 22 Mio. € (26 Mio. US$) aus Serie-B-Finanzier..

More news

Analyst Recommendations on EVOTEC SE

10/19	EVOTEC : Baader Bank keeps its Buy rating	MD
10/13	EVOTEC : Buy rating from RBC	MD
10/13	EVOTEC : Baader Bank gives a Buy rating	MD

More recommendations

Stock Trading Strategies

	EVOTEC SE - 07/24
Back on price levels to sell

SELL

More Stock Trading Analysis

Provided by Scoopnest.com

Chart EVOTEC SE

Duration : Period :

Evotec SE Technical Analysis Chart | MarketScreener

Full-screen chart

Technical analysis trends EVOTEC SE

	Short Term	Mid-Term	Long Term
Trends	Bullish	Neutral	Neutral

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	BUY
Number of Analysts	9
Average target price	30,33 €
Last Close Price	23,18 €
Spread / Highest target	55,3%
Spread / Average Target	30,9%
Spread / Lowest Target	20,8%

Consensus

EPS Revisions

More Estimates Revisions

Managers

Name	Title
Werner Lanthaler	Chief Executive Officer
Wolfgang Plischke	Chairman-Supervisory Board
Craig L. Johnstone	Chief Operating Officer & Member-Management Board
Enno Spillner	Chief Financial Officer
Cord E. Dohrmann	Chief Scientific Officer

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

EVOTEC SE	0.56%	4 461



LONZA GROUP AG	62.00%	47 011
SEAGEN INC.	73.04%	34 401
IQVIA HOLDINGS INC.	9.54%	32 445
CELLTRION, INC.	31.22%	28 807
MODERNA, INC.	249.54%	26 978

More Results